Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Assessment of literacy and numeracy skills related to non-steroidal anti-inflammatory drug labels.

Jang SM, Jiang R, Grabe D, Pai AB.

SAGE Open Med. 2019 Mar 7;7:2050312119834119. doi: 10.1177/2050312119834119. eCollection 2019.

2.

Iron Oxide Nanoparticle Formulations for Supplementation.

Pai AB.

Met Ions Life Sci. 2019 Jan 14;19. pii: /books/9783110527872/9783110527872-012/9783110527872-012.xml. doi: 10.1515/9783110527872-012. Review.

PMID:
30855107
3.

Patient-selected media and knowledge of risk to kidneys of nonsteroidal anti-inflammatory drugs.

Pai AB, Engling J, Chapman C, Volk R, Costello G, Codd C, Ashjian E, Wright-Nunes J.

J Am Pharm Assoc (2003). 2019 May - Jun;59(3):329-335. doi: 10.1016/j.japh.2019.01.012. Epub 2019 Mar 2.

PMID:
30833128
4.

Fostering Innovation in Symptom Management among Hemodialysis Patients: Paths Forward for Insomnia, Muscle Cramps, and Fatigue.

Flythe JE, Hilliard T, Lumby E, Castillo G, Orazi J, Abdel-Rahman EM, Pai AB, Rivara MB, St Peter WL, Weisbord SD, Wilkie CM, Mehrotra R; Kidney Health Initiative Prioritizing Symptoms of ESRD Patients for Developing Therapeutic Interventions Stakeholder Meeting Participants.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):150-160. doi: 10.2215/CJN.07670618. Epub 2018 Nov 5.

PMID:
30397026
5.

Need for a Judicious Use of Nonsteroidal Anti-inflammatory Drugs to Avoid Community-Acquired Acute Kidney Injury.

Pai AB, Divine H, Marciniak M, Morreale A, Saseen JJ, Say K, Segal AR, Norton JM, Narva AS.

Ann Pharmacother. 2019 Jan;53(1):95-100. doi: 10.1177/1060028018789174. Epub 2018 Jul 18.

PMID:
30019916
6.

In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations.

Pai AB, Pai MP, Meyer DE, Bales BC, Cotero VE, Zheng N, Jiang W.

Regul Toxicol Pharmacol. 2018 Aug;97:17-23. doi: 10.1016/j.yrtph.2018.05.014. Epub 2018 May 29.

PMID:
29857115
7.

Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study.

Flythe JE, Hilliard T, Castillo G, Ikeler K, Orazi J, Abdel-Rahman E, Pai AB, Rivara MB, St Peter WL, Weisbord SD, Wilkie C, Mehrotra R.

Clin J Am Soc Nephrol. 2018 May 7;13(5):735-745. doi: 10.2215/CJN.10850917. Epub 2018 Mar 20.

8.

Why Nomenclature for Pharmacist-Led Interventions Matters: Conquering the State of Confusion.

Pai AB.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):198-200. doi: 10.2215/CJN.13601217. Epub 2018 Jan 2. No abstract available.

9.

Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.

Pai AB.

Ann N Y Acad Sci. 2017 Nov;1407(1):17-25. doi: 10.1111/nyas.13461. Epub 2017 Oct 13. Review.

10.

Health Literacy and Medication Management in Chronic Kidney Disease.

Galura G, Pai AB.

Health Lit Res Pract. 2017 Jul 31;1(3):e109-e115. doi: 10.3928/24748307-20170607-01. eCollection 2017 Jul. No abstract available.

11.

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.

Pai AB, Meyer DE, Bales BC, Cotero VE, Pai MP, Zheng N, Jiang W.

Clin Transl Sci. 2017 May;10(3):194-200. doi: 10.1111/cts.12443. Epub 2017 Feb 3.

12.

Drug Transporter Function--Implications in CKD.

Schwenk MH, Pai AB.

Adv Chronic Kidney Dis. 2016 Mar;23(2):76-81. doi: 10.1053/j.ackd.2016.01.016. Review.

PMID:
26979146
13.

It is all About "ADME".

Pai AB.

Adv Chronic Kidney Dis. 2016 Mar;23(2):61-2. doi: 10.1053/j.ackd.2016.02.001. No abstract available.

PMID:
26979143
14.

Iron-based phosphate binders--a new element in management of hyperphosphatemia.

Pai AB, Jang SM, Wegrzyn N.

Expert Opin Drug Metab Toxicol. 2016;12(1):115-27. doi: 10.1517/17425255.2016.1110573. Epub 2015 Nov 16. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2016;12(1):v.

PMID:
26572591
15.

Considerations and challenges in defining optimal iron utilization in hemodialysis.

Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology.

J Am Soc Nephrol. 2015 Jun;26(6):1238-47. doi: 10.1681/ASN.2014090922. Epub 2014 Dec 26. Review.

16.

NSAID-avoidance education in community pharmacies for patients at high risk for acute kidney injury, upstate New York, 2011.

Jang SM, Cerulli J, Grabe DW, Fox C, Vassalotti JA, Prokopienko AJ, Pai AB.

Prev Chronic Dis. 2014 Dec 18;11:E220. doi: 10.5888/pcd11.140298.

17.

Keeping kidneys safe: the pharmacist's role in NSAID avoidance in high-risk patients.

Pai AB.

J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):e15-23; quiz e24-5. doi: 10.1331/JAPhA.2015.15506. Review.

PMID:
25503987
18.

Evaluating plasma pharmacokinetics of intravenous iron formulations: judging books by their covers?

Pai AB.

Clin Pharmacokinet. 2015 Apr;54(4):323-4. doi: 10.1007/s40262-014-0218-2. No abstract available.

PMID:
25445844
19.

Colitis after polytrauma: case report.

Carter WE, Darko IA, Chandan P, Pai AB.

J Rehabil Res Dev. 2014;51(4):655-60. doi: 10.1682/JRRD.2013.04.0100.

20.

Can American Board of Physical Medicine and Rehabilitation Part 2 board examination scores be predicted from rotation evaluations or mock oral examinations?

Engel J, Pai AB, Walker WC.

Am J Phys Med Rehabil. 2014 Dec;93(12):1051-6. doi: 10.1097/PHM.0000000000000126.

PMID:
24919078
21.

Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.

Pai AB, Cardone KE, Manley HJ, St Peter WL, Shaffer R, Somers M, Mehrotra R; Dialysis Advisory Group of American Society of Nephrology.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1988-99. doi: 10.2215/CJN.01420213. Epub 2013 Aug 29.

22.

Endotoxin binding by sevelamer: potential impact on nutritional status.

Kubotera N, Prokopienko AJ, Garba AO, Pai AB.

Int J Nephrol. 2013;2013:954956. doi: 10.1155/2013/954956. Epub 2013 Jan 17.

24.

Lipoteichoic acid from Staphylococcus aureus induces lung endothelial cell barrier dysfunction: role of reactive oxygen and nitrogen species.

Pai AB, Patel H, Prokopienko AJ, Alsaffar H, Gertzberg N, Neumann P, Punjabi A, Johnson A.

PLoS One. 2012;7(11):e49209. doi: 10.1371/journal.pone.0049209. Epub 2012 Nov 15.

25.

Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?

Pai AB, Garba AO.

J Blood Med. 2012;3:77-85. doi: 10.2147/JBM.S29204. Epub 2012 Aug 29.

26.

Prevalence of chronic kidney disease in patients undergoing cardiac rhythm device removal.

Asif A, Carrillo R, Garisto JD, Monrroy M, Khan RA, Castro H, Merrill D, Ali AS, Pai AB, Waldman J, Salman L.

Semin Dial. 2013 Jan-Feb;26(1):111-3. doi: 10.1111/j.1525-139X.2012.01101.x. Epub 2012 Jul 11.

PMID:
22780814
27.

Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.

Conner TA, McQuade C, Olp J, Pai AB.

Biometals. 2012 Oct;25(5):961-9. doi: 10.1007/s10534-012-9562-6. Epub 2012 Jun 17.

PMID:
22706571
28.

Patient safety in rehabilitation medicine: traumatic brain injury.

Pai AB, Zadov Y, Hickman A.

Phys Med Rehabil Clin N Am. 2012 May;23(2):349-70. doi: 10.1016/j.pmr.2012.02.009. Epub 2012 Apr 10. Review.

PMID:
22537698
29.

Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.

Pai AB, Conner T, McQuade CR, Olp J, Hicks P.

Biometals. 2011 Aug;24(4):603-13. doi: 10.1007/s10534-011-9409-6. Epub 2011 Jan 13.

PMID:
21229380
30.

Medication-related problems in CKD.

Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ.

Adv Chronic Kidney Dis. 2010 Sep;17(5):404-12. doi: 10.1053/j.ackd.2010.06.004. Review.

PMID:
20727510
31.

CKD: Pharmacotherapy in a House of Mirrors.

Moore CL, Pai AB.

Adv Chronic Kidney Dis. 2010 Sep;17(5):381-3. doi: 10.1053/j.ackd.2010.06.005. No abstract available.

PMID:
20727507
32.

Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects.

Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS.

Clin Pharmacol Ther. 2010 Aug;88(2):237-42. doi: 10.1038/clpt.2010.80. Epub 2010 Jun 30.

PMID:
20592725
33.

The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.

Assimon MM, Mousa S, Shaker O, Pai AB.

Consult Pharm. 2010 Jan;25(1):41-54. doi: 10.4140/TCP.n.2010.41. Review.

PMID:
20211816
34.

Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study.

Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Manley H.

Pharmacotherapy. 2009 Dec;29(12):1433-40. doi: 10.1592/phco.29.12.1433.

PMID:
19947803
35.

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

Pai AB, Shepler BM.

Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554. Review.

PMID:
19397463
36.

Estimation of creatinine clearance in morbidly obese patients.

Demirovic JA, Pai AB, Pai MP.

Am J Health Syst Pharm. 2009 Apr 1;66(7):642-8. doi: 10.2146/ajhp080200.

PMID:
19299371
37.

Correlation between the renal quality of life profile and short form-36 in a United States hemodialysis population.

Boyd AV, McQuade CR, Conner T, Manley HJ, Pai AB.

Hemodial Int. 2009 Jan;13(1):89-90. doi: 10.1111/j.1542-4758.2009.00341.x. No abstract available.

PMID:
19210284
38.

Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a 2-year randomized, controlled study.

Pai AB, Boyd A, Chavez A, Manley HJ.

Hemodial Int. 2009 Jan;13(1):72-9. doi: 10.1111/j.1542-4758.2009.00328.x.

PMID:
19210281
39.

Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.

Pai AB, Norenberg J, Boyd A, Raj D, Chan LN.

Clin Ther. 2007 Dec;29(12):2699-705. doi: 10.1016/j.clinthera.2007.12.024.

PMID:
18201586
40.

Elevated serum creatinine levels associated with fenofibrate therapy.

McQuade CR, Griego J, Anderson J, Pai AB.

Am J Health Syst Pharm. 2008 Jan 15;65(2):138-41. doi: 10.2146/ajhp070005.

PMID:
18192258
41.
42.

Sampling for international normalized ratios in patients on hemodialysis with central venous catheters.

Boyd A, Dunne A, Townsend K, Pai AB.

Nephrol Nurs J. 2006 Jul-Aug;33(4):408-11.

PMID:
17001998
43.

Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis.

Pai AB, Pai MP.

Adv Chronic Kidney Dis. 2006 Jul;13(3):259-70. Review.

PMID:
16815231
44.

Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm.

Pai AB, Pai MP.

Am J Health Syst Pharm. 2004 Sep 1;61(17):1812-6.

PMID:
15462252
45.

The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.

Pai AB, Smeeding JE, Brook RA.

Curr Med Res Opin. 2004 Jul;20(7):991-9. Review.

PMID:
15265243

Supplemental Content

Support Center